Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12514827 | 0.86 | ALDH1A1 (0.35) | SMN1; SMN2ALDH1A1HSD17B10GAA | |
| SCHEMBL445120 | 0.82 | NAAA (0.39) | ALDH1A1 | |
| SCHEMBL27869581 | 0.75 | NAAA (0.34) | ALDH1A1 | |
| SCHEMBL223951 | 0.75 | NAAA (0.34) | ALDH1A1 | |
| SCHEMBL12440385 | 0.73 | GAA (0.34) | ALDH1A1HSD17B10GAA | |
| SCHEMBL10087936 | 0.70 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1HSD17B10GAA | |
| SCHEMBL26267516 | 0.70 | NAAA (0.35) | SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL13235996 | 0.69 | MEN1 (0.41) | SMN1; SMN2GAA | |
| SCHEMBL20882707 | 0.68 | GAA (0.46) | SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL28061919 | 0.68 | NAAA (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524691-B2 | Phosphonated rifamycins and uses thereof for the prevention and treatment of bone and joint infections | THE MEDICINES COMPANY (US) | 2013-09-03 | — | — | US | disclosed |
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | TARGANTA THERAPEUTICS CORP. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178001-A1 | PHOSPHONATED RIFAMYCINS AND USES THEREOF FOR THE PREVENTION AND TREATMENT OF BONE AND JOINT INFECTIONS | BPGM, SOST, PSPH | SMN1; SMN2 4485/4885ALDH1A1 3493/4885HSD17B10 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.